On Wednesday, Novo Nordisk A/S (NYSE:NVO) and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.
The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programs, primarily focused on cardiovascular disease.
Valo was eligible to receive up to $2.7 billion in milestone payments, plus R&D funding and potential royalty payments.
Also Read: Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Under the terms of the expanded agreement, Valo is entitled to receive an upfront payment, equity investment, and a potential near-term milestone payment totaling $190 million and is now eligible to receive milestone payments for up to 20 drug programs, an addition of 9 new drug programs, totaling approximately $4.6 billion, plus R&D funding and potential royalty payments.
The expanded collaboration will continue to leverage Valo's Opal Computational Platform's capabilities, key joint capabilities in human data and genetics, and Novo Nordisk's expertise in cardiometabolic diseases.
The collaboration has already identified several novel targets that may form the basis of differentiated cardiometabolic drug programs, and the companies are actively working on multiple small-molecule preclinical drug discovery programs.
On Tuesday, Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for metabolic disease.
The partnership between Novo Nordisk and Variant Bio aims to identify and validate multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
Under the terms of the agreement, Novo Nordisk said it would pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments on targets that arise from the collaboration.
Price Action: NVO stock is up 2.95% at $85.80 at the last check on Wednesday.
- Helen Of Troy Sales Decline As Beauty Products Demand Softens; Shares Plunge
Photo via Shutterstock
周三，诺和诺德A/S（纽约证券交易所代码：NVO）和Valo Health, Inc.签订了扩大协议，以发现和开发肥胖、2型糖尿病和心血管疾病的新疗法。
两家公司最初于2023年9月合作达成了一项协议，该协议允许开发多达11个药物项目，主要针对心血管疾病。
Valo有资格获得高达27亿美元的里程碑付款，外加研发资金和潜在的特许权使用费。
另请阅读：Viking Therapeutics、Structure Therapeutics被定位为减肥产品的主要制药合作伙伴：分析师
根据扩大协议的条款，Valo有权获得总额为1.9亿美元的预付款、股权投资和潜在的近期里程碑付款，现在有资格获得多达20个药物项目、另外9个总额约为46亿美元的新药项目的里程碑式付款，外加研发资金和潜在的特许权使用费。
扩大合作将继续利用Valo的Opal计算平台的能力、人类数据和遗传学方面的关键联合能力以及Novo Nordisk在心脏代谢疾病方面的专业知识。
该合作已经确定了几种可能构成差异化心脏代谢药物计划基础的新靶标，两家公司正在积极开展多个小分子临床前药物发现计划。
周二，由基因组学驱动的药物发现公司Variant Bio宣布与诺和诺德进行为期多年的研究合作，以发现代谢性疾病的新靶标。
Novo Nordisk和Variant Bio之间的合作旨在识别和验证具有足够人类遗传证据的多个新靶标，以启动以人为本的药物发现计划。
根据协议条款，诺和诺德表示将向Variant Bio支付预付款和总额高达5000万美元的额外短期研发资金，外加潜在的期权和里程碑付款，以实现合作产生的目标。
价格走势：在周三的最后一次支票中，NVO股价上涨2.95％，至85.80美元。
- 随着美容产品需求的疲软，特洛伊海伦的销售额下降；股价暴跌
照片来自 Shutterstock
